Almac Group unveils Almac One solution for clinical trial supply chain
Category: #health  By Mateen Dalal  Date: 2019-03-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

Almac Group unveils Almac One solution for clinical trial supply chain

Almac One™ would help sponsors to face the challenges existing in the drug development market

It provide a single set of process to sponsors and enable greater visibility and control of supply chain

Reports confirm that Almac Group has recently introduced Almac One™, the first unified Clinical Trial Solution, for redefining the experience of a clinical supply chain and create an end-to-end responsive process which would enhance the accuracy and visibility across the clinical study lifecycle.

The company has stated that the drug development market is continuously evolving with common challenges faced, like limited inventory, expensive investigational products as well as globalization of clinical trials. Supposedly, a key difficulty which sponsors are facing today is the disconnect existing throughout the clinical supply chain owing to variable recruitment patterns and demand from patients, leading to costly and disjointed trials with frequently missed targets.

According to an Almac Group press release, the company has leveraged more than thirty years of experience in Clinical Supplies delivery and services, along with Interactive Response Technology for developing Almac One™. It also aimed to fulfil the need for more smart, informed and timely decision making for aligning vital study data.

Almac mentioned that the Almac One™ solution brings together expert consultants from across the clinical logistics, packaging and IRT spectrum to offer a single set of process to sponsors, in combination with close-loop technology for managing data end-to-end which enables greater visibility and control in a supply chain across a study’s lifecycle. This is achieved by the alignment of patient recruitment, clinical IRT and supply strategies for delivering a seamless flow of data. 

Managing Director and President of Almac Clinical Technologies, Val Higgins said that Almac One™ would offer sponsors a more streamlined approach towards global supply chain and will empower clients to make faster, more accurate decisions for managing their studies. He added that the company’s latest development is a part of its ongoing program of solutions targeted at helping clients face the challenges which clinical supply chain may bring in the future.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
By Mateen Dalal

Ambrx will receive additional development payments with Bristol-Meyers’ initiation of the Phase 1 clinical trial for Relaxin Ambrx Inc., a biopharmaceutical company focused on developing protein therapeutics, has recently announced that Bristo...

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
By Mateen Dalal

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acqu...

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...